Missed the webinar? Here are Investing.com’s top 10 stock picks for 2026
Traws Pharma, Inc. (NASDAQ:TRAW) announced Friday that its stockholders approved several proposals at the company’s 2025 Annual Meeting held virtually on November 21. The information is based on a press release statement and a recent SEC filing. The micro-cap pharmaceutical company, currently valued at approximately $21.6 million, has seen its shares rise 16.9% over the past week and an impressive 100% over the last six months, according to InvestingPro data.
Shareholders voted to amend and restate the company’s 2021 Incentive Compensation Plan, increasing the number of authorized shares by 1,500,000 and extending the plan’s term until November 20, 2035. The amended plan was previously approved by the board on October 7, pending stockholder approval, and became effective following the vote.
At the meeting, 3,419,727 shares, or approximately 48.0% of the company’s 7,125,832 outstanding shares as of the October 2 record date, were represented in person or by proxy, establishing a quorum.
All seven nominees to the board of directors were elected to serve until the 2026 Annual Meeting. The elected directors and their votes for and withheld were as follows:
- Iain Dukes, D.Phil.: 2,366,179 for, 37,016 withheld
- Werner Cautreels, Ph.D.: 2,364,118 for, 39,077 withheld
- Trafford Clarke, Ph.D.: 2,364,172 for, 39,023 withheld
- John Leaman, M.D.: 2,367,095 for, 36,100 withheld
- Nikolay Savchuck, Ph.D.: 2,364,157 for, 39,038 withheld
- M. Teresa Shoemaker: 2,362,913 for, 40,282 withheld
- Jack E. Stover: 2,363,812 for, 39,383 withheld
Other proposals approved included an advisory vote on executive compensation, with 2,293,949 votes in favor, and a decision to hold future advisory votes on executive compensation every two years, based on 1,923,712 votes supporting a biennial frequency. While Traws Pharma was not profitable over the last twelve months, InvestingPro analysis shows analysts predict the company will be profitable this year, with an EPS forecast of $21.11 for fiscal year 2025.
Stockholders also ratified the selection of KPMG LLP as the company’s independent auditor for the fiscal year ending December 31, 2025, with 3,350,178 votes in favor.
A proposal to adjourn the meeting, if necessary to solicit additional proxies, was approved but not acted upon, as all other proposals passed.
Traws Pharma is incorporated in Delaware and its common stock is listed on The Nasdaq Stock Market LLC under the symbol TRAW.
In other recent news, Traws Pharma has initiated Phase 2 trials for its COVID-19 treatment, ratutrelvir, which does not require ritonavir. The trials include a non-inferiority study comparing ratutrelvir to PAXLOVID and a single-arm trial for patients ineligible for PAXLOVID. Additionally, ChemDiv will continue providing Chemistry, Manufacturing, and Controls (CMC) services for ratutrelvir during these trials. Traws Pharma’s Compensation Committee has approved stock options for five executives, including CEO Iain Dukes and CFO Charles Parker, with each option priced at $3.01 per share. In corporate governance updates, John Leaman has been appointed to the board of directors, and interim tags have been removed from key executives Dukes and Parker. Annovis Bio has appointed Mark Guerin as its new CFO; Guerin previously served as CFO at Onconova Therapeutics, which merged with Trawsfynydd Therapeutics to form Traws Pharma. These developments reflect Traws Pharma’s ongoing efforts in advancing its COVID-19 treatment and strengthening its leadership team.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.